

30 April 2025

Cizzle Biotechnology Holdings plc

("Cizzle", "Cizzle Biotechnology", or the "Company")

Final results for the year ended 31 December 2024

Cizzle Biotechnology, the UK based diagnostics developer of early cancer tests, announces the publication of the Company's Annual Report and Financial Statements for the year ended 31 December 2024 ("Annual Report").

The Annual Report is available via http://www.rns-pdf.londonstockexchange.com/rns/8506G_1-2025-4-30.pdf and will shortly be available to view on the on the National Storage Mechanism (NSM) and the Company's website: <https://cizzlebiotechnology.com>

Enquiries:

Cizzle Biotechnology Holdings plc
Allan Syms (Executive Chairman)

Via IFC Advisory

Allenby Capital Limited
John Depasquale / Piers Shimwell (Corporate Finance)
Stefano Aquilino / Amrit Nahal (Sales and Corporate Broking)

+44(0) 20 3328 5656

IFC Advisory Limited
Tim Metcalfe
Florence Staton

+44(0) 20 3934 6630

About Cizzle Biotechnology

Based on the pioneering work of Professor Coverley and colleagues, on a naturally occurring variant of the cell nuclear protein CIZ1, the CIZ1B biomarker is highly associated with the presence of early-stage cancer. The company has developed CIZ1B into a non-invasive, cost-effective blood test to help in the early detection of lung cancer and has now entered into commercial royalty-bearing arrangements to license its proprietary technology, and into collaborations with centres of excellence in cancer care. Cizzle was admitted to the Standard segment of the main market of the London Stock Exchange in May 2021.

For more information, please see <https://cizzlebiotechnology.com>

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.